- 1 **Article Summary Line:** In South Africa, after a third wave of SARS-CoV-2 infections,
- 2 seroprevalence was 60% in a rural and 70% in an urban community, with case-to-infection, -
- 3 hospitalization and -fatality ratios similar to the second wave.
- 4 Running title: SARS-CoV-2 seroprevalence, South Africa, 2021
- **Keywords:** SARS-CoV-2, seroprevalence, case-to-infection ratio, case-to-hospitalization 5
- ratio, case-to-fatality ratio 6

- SARS-CoV-2 seroprevalence in a rural and urban community household cohort in 8
- 9 South Africa, after the third wave, April-November 2021
- Jackie Kleynhans (MPH), Stefano Tempia (PhD), Nicole Wolter (PhD), Anne von Gottberg 10
- (PhD), Jinal N. Bhiman (PhD), Amelia Buys (MTech), Jocelyn Moyes (MD), Meredith L. 11
- 12 McMorrow (MD), Kathleen Kahn (PhD), F. Xavier Gómez-Olivé (PhD), Stephen Tollman
- (PhD), Neil A. Martinson (MD), Floidy Wafawanaka (MSc), Limakatso Lebina (MD), 13
- Jacques du Toit (MD), Waasila Jassat (MD), Mzimasi Neti (MPH), Marieke Brauer (MMed 14
- Path), Cheryl Cohen (PhD), for the PHIRST-C Group¹ 15
- **Author affiliations** 16
- National Institute for Communicable Diseases of the National Health Laboratory Service, 17
- Johannesburg, South Africa (J. Kleynhans, S. Tempia, N. Wolter, A. von Gottberg, J.N. 18
- 19 Bhiman, A. Buys, J. Moyes, W. Jassat, M. Neti, C. Cohen)
- 20 University of the Witwatersrand, Johannesburg, South Africa (J. Kleynhans, S. Tempia, N.
- Wolter, A. von Gottberg, J.N. Bhiman, J. Moyes, C. Cohen) 21
- Centers for Disease Control and Prevention, Atlanta, Georgia, United States of America (S. 22
- 23 Tempia, M.L. McMorrow)
- Influenza Program, Centers for Disease Control and Prevention, Pretoria, South Africa (M.L. 24
- McMorrow) 25
 - NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 26 MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), University
- of the Witwatersrand, Johannesburg, South Africa (K. Kahn, F.X. Gómez-Olivé, S. Tollman,
- 28 F. Wafawanaka, J. du Toit)
- 29 Perinatal HIV Research Unit (PHRU), University of the Witwatersrand, Johannesburg, South
- 30 Africa (N.A. Martinson, L. Lebina)
- 31 Johns Hopkins University Center for TB Research, Baltimore, Maryland, United States of
- 32 America (N.A. Martinson)
- 33 Africa Health Research Institute, Durban, South Africa (L. Lebina)
- 34 Ampath Pathology, Pretoria, South Africa (M. Brauer)
- 35 ¹Additional members of the PHIRST-C group who contributed to this manuscript are listed at
- 36 the end of this article
- **37 Abstract (words 50/50)**
- 38 By November 2021, after the third SARS-CoV-2 wave in South Africa, seroprevalence was
- 39 60% (95% CrI 56% -64%) in a rural and 70% (95% CrI 56% -64%) in an urban community;
- 40 highest in individuals aged 13-18 years. High seroprevalence prior to Omicron emergence
- may have contributed to reduced severity observed in the 4th wave.
- 43 Word count (756/800)

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

South Africa so far experienced four waves of SARS-CoV-2 infection, the fourth dominated by the Omicron variant of concern (1). Data on the proportion of the population with serologic evidence of previous infection at the time of Omicron emergence are important to contextualise the observed rapid increases and subsequent quick decline in case numbers, (1) as well as the lower severity compared to previous variants (2). We previously described the seroprevalence of SARS-CoV-2 in the PHIRST-C cohort in a rural and an urban community at five time points, from July 2020 to March 2021 (3). Using the same methods (Appendix), we report seroprevalence at four additional time points through November 27, 2021, spanning the third Delta-dominated wave (Appendix Figure 1), ending the week Omicron was identified (4). We tested sera using the Roche Elecsys® Anti-SARS-CoV-2 assay (Roche Diagnostics, Rotkreuz, Switzerland); cut-off index (COI)≥1.0 considered indication of prior infection. The immunoassay detects nucleocapsid (N) antibodies, thus not detecting post-vaccination antibody responses. We obtained seroprevalence 95% credible intervals (CrIs) by using Bayesian inference with 10,000 posterior draws (5). We estimated the age-and sex-adjusted number of infections, and ageadjusted diagnosed cases, hospitalizations, deaths, case-to-infection ratio (CIR), case-tohospitalization ratio (HIR) and in-hospital and excess death case-to-fatality ratio (FIR) as described previously (3) and in Appendix. Third wave infections were defined as participants with a paired blood draw (BD) 5 (collected March 22 – April 11, 2021) and BD9 (collected November 15 - 27, 2021) sample, seronegative at BD5 and seropositive at BD9, or seropositive at BD5 but had a \geq 2-fold higher COI in BD9 (as possible re-infections after BD5 occurred, n=38, detailed in Appendix). Vaccination status was obtained through reviewing vaccine cards kept at home. The study was approved by the University of the Witwatersrand Human Research Ethics Committee (Reference 150808) and the US Centers for Disease Control and Prevention relied on local clearance (IRB #6840).

- 69 Overall, pre-third wave (BD5) SARS-CoV-2 seroprevalence adjusted for assay sensitivity 70 and specificity was 26% (95% CrI 22%-29%) in the rural and 41% (95% CrI 37%-45%) in
- the urban community. After the third wave (BD9), overall seroprevalence increased to 60% 71
- 72 (95% CrI 56%-64%) in the rural community and 70% (95% CrI 66%-74%) in the urban
- 73 community (Figure, Appendix Table 1). In both communities the largest increase in
- 74 seroprevalence was seen in children aged 13-18 years, who also had the highest
- 75 seroprevalence of all ages after the third wave: 80% (95% CrI 70%-88%) in the rural
- community and 83% (95% CrI 73%-90%) in the urban community, a 49% and 19% increase, 76
- 77 respectively.
- During the third wave of infections, the incidence at the rural site was 39% (95%CrI 24%-78
- 79 55%), resulting in a CIR of 3% (95%CI 2%-5%). There was a 0.5% (95%CI 0.3%-0.7%) HIR
- 80 and an in-hospital FIR of 0.1% (95%CI 0.1%-0.2%) and an excess deaths FIR of 0.5%
- (95%CI 0.4%-0.8%, Figure and Appendix Figure 2). 81
- In the urban community the incidence during the third wave was 40% (95%CrI 26%-54%). 82
- There was a 5% (95%CI 4%-8%) CIR and 2% (95%CI 2%-4%) HIR. The in-hospital FIR 83
- was 0.4% (95% CI 0.3%-0.6%) and excess deaths FIR 0.6% (95% CI 0.4-0.9%, Figure and 84
- Appendix Figure 2). 85
- At the time of BD9, for those individuals in the rural community with a known vaccination 86
- status, 29% (25/85) of individuals aged 35-59 years, and 38% (16/42) aged ≥60 years were 87
- fully vaccinated against SARS-CoV-2 (one dose of Johnson & Johnson or two doses of 88
- Pfizer-BioNTech). In the urban community, 42% (47/111) aged 35-59 years and 58% (31/53) 89
- 90 aged ≥60 years were fully vaccinated (Appendix Table 2).
- 91 Taken together, by the end of November 2021, just prior to the emergence of Omicron, the
- 92 combined proportion of individuals with either serologic evidence of previous infection (at

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

any draw) and/or fully vaccinated was 62% (389/631) at the rural and 72% (411/568) at the urban community (Appendix Table 3). After the third wave of infections in South Africa, we observed a \geq 60% overall seroprevalence due to SARS-CoV-2 infection, ranging from 43% in rural community children aged <5 years to 83% in urban community children aged 13-18 years (Figure). CIF, HIR and FIRs were similar between the second and third waves. Similar to our data, a study from Gauteng Province found seroprevalence of 56%-80% due to natural infection prior to the emergence of Omicron (6). The high seroprevalence prior to Omicron emergence may have contributed to reduced severity observed in the 4th wave (2). Future studies examining SARS-CoV-2 attack rates using paired serology will be important to help understand how immunity affects disease severity in the population during the fourth Omicron wave. Additional members of the PHIRST-C group who contributed to this manuscript Kgaugelo Patricia Kgasago, Linda de Gouveia, Maimuna Carrim, Mignon du Plessis, Retshidisitswe Kotane, Tumelo Moloantoa Acknowledgements All individuals participating in the study, field teams for their hard work and dedication to the study, the laboratory teams, the PHIRST-C scientific and safety committee, the national SARS-CoV-2 NICD surveillance team, NICD IT. Disclaimer The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the CDC. **Funding**

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

This work was supported by the National Institute for Communicable Diseases of the National Health Laboratory Service and the US Centers for Disease Control and Prevention (cooperative agreement number 6U01IP001048-04-02 awarded to C Cohen). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. **Potential conflicts of interest** Cheryl Cohen reports receiving grant funds from US-Centers for Disease Control and Prevention, Wellcome Trust and South African Medical Research Council. Nicole Wolter and Anne von Gottberg report receiving grant funds from Sanofi and Gates Foundation. All other authors have no competing/conflict of interest. Data availability The investigators welcome enquiries about possible collaborations and requests for access to the dataset. Data will be shared after approval of a proposal and with a signed data access agreement. Investigators interested in more details about this study, or in accessing these resources, should contact the corresponding author. References National Institute for Comminicable Diseases. COVID-19 Weekly Epidemiology Brief Week 3. 1. 2022 26 Janaury 2022 [cited 31 Janaury 2022; Available from: https://www.nicd.ac.za/wpcontent/uploads/2022/01/COVID-19-Weekly-Epidemiology-Brief-week-3-2022.pdf Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, et al. Early assessment of the 2. clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. The Lancet. 2022;339(10323):437-46.

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

3. Kleynhans J, Tempia S, Wolter N, von Gottberg A, Bhiman J, Buys A, et al. SARS-CoV-2 Seroprevalence in a Rural and Urban Household Cohort during First and Second Waves of Infections, South Africa, July 2020–March 2021. Emerging Infectious Disease journal. 2021;27(12):3020. World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of 4. Concern. 2021 26 November 2021 [cited 5 January 2021 5 January 2021]; Available from: https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2variant-of-concern 5. Larremore DB, Fosdick BK, Bubar KM, Zhang S, Kissler SM, Metcalf CJE, et al. Estimating SARS-CoV-2 seroprevalence and epidemiological parameters with uncertainty from serological surveys. Elife. 2021;10:e64206. 6. Madhi SA, Kwatra G, Myers JE, Jassat W, Dhar N, Mukendi CK, et al. South African Population Immunity and Severe Covid-19 with Omicron Variant. medRxiv. 2021:2021.12.20.21268096. **Biographical Sketch** Jackie Kleynhans is an epidemiologist in Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases. She holds a Master's degree in Microbiology and Masters of Public Health from the University of Pretoria, and is an alumnus of the South African Field Epidemiology Training Programme. Her interests include the epidemiology of respiratory diseases like influenza and COVID-19, vaccine impact studies and modelling of infectious disease transmission dynamics. Address for correspondence Jackie Kleynhans, Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, 1 Modderfontein Road, Sandringham, 2192, Johannesburg, South Africa; email: jackiel@nicd.ac.za




Figure. SARS-CoV-2 seroprevalence at each blood collection by age group in the a) rural and b) urban community March 2020 - November 2021, South Africa.

Baseline (BD1) July 20 – September 17, 2020; second draw (BD2) September 21 – October 10, 2020; third draw (BD3) November 23 – December 12, 2020; fourth draw (BD4) January, 25 – February 20, 2021; fifth draw (BD5) March 22 – April 11, 2021; sixth draw (BD6) May 20 – June 9, 2021; seventh draw (BD7) July 19 – August 5, 2021; eighth draw (BD8) September 13 – 25, 2021; ninth draw (BD9) November 15 – 27, 2021. Vertical capped lines represent 95% credible interval. Seroprevalence estimates adjusted for sensitivity and specificity of assay.